5α-还原酶抑制剂治疗前列腺增生体积≥30 mL患者临床疗效观察  

Clinical study of 5 alpha reductase inhibitors and prostate volume

作　　者：刘荣耀[1] 刘百成[1] 王旺龙[1] 刘泽民 李志灵[1] 张宏宇[1] 郭建忠[1] 刘晶[1] 段晓明[1] 

机构地区：[1]吕梁市人民医院,山西吕梁033000

出　　处：《基层医学论坛》2017年第25期3317-3319,共3页The Medical Forum

基　　金：吕梁市科技攻关项目(2016sfgg067-10)

摘　　要：目的研究5α还原酶抑制剂对前列腺体积≥30 mL前列腺增生患者的治疗效果。方法将我院泌尿外科2016年1月—2017年1月住院、门诊200例前列腺体积≥30 mL前列腺增生患者随机分为2组,对照组:盐酸坦洛新缓释胶囊0.2 mg口服,每天1次;治疗组:非那雄胺5 mg口服qd,盐酸坦洛新缓释胶囊0.2 mg口服,每天1次。2组用药6个月后,根据最大尿流率(mL/s)、前列腺体积(mL)、残余尿量(mL)、I-PSS评分评定疗效。结果治疗组和对照组患者最大尿流率均较治疗前提高,前列腺体积、残余尿、I-PSS评分均较治疗前降低,且治疗组的改善幅度优于对照组,差异有统计学意义(P<0.05)。结论 5α还原酶抑制剂对前列腺体积≥30mL前列腺增生患者的治疗有明显效果。Objective To offer the optimum treating protocol for BPH patients by investigating the outcome of 5 alpha reductase inhibitors application for patients with various volume of prostate.Methods 200 patients who were admitted to our hospital from January 2016 to January 2017 were enrolled and divided into two groups according to the volume of prostate（ ≥30mL）.The two groups were further randomLy divided into experimental group and control group repectively. the experimental groups received Finasteride 5mg qd plus Tamsulosin Hydrochloride Sustained Release Capsules 0.2mg qd,while control groups received only Tamsulosin Hydrochloride Sustained Release Capsules 0.2mg qd. The outcome was evaluated by maximum urine flow rate,volume of prostate,residual urine volume and I-PSS score 6 months later.Results For the group（≥30mL）,all the indexwas improved after treatment（P〈0.05）and the difference is significant between the experimental and control group（P〈0.05）.Conclusion 5 alpha reductase inhibitors has better and more obvious treating effect on prostate of volume unless than 30 mL.

关 键 词：前列腺增生 体积≥30 ML 5Α还原酶抑制剂 临床疗效 

分 类 号：R697.3[医药卫生—泌尿科学]